EMA approved 104 human medicines in 2025: what changed
Decision brief
Answer first · skim in under a minute
EMA recommended 104 medicines for marketing authorisation in 2025, with 38 new active substances and a record biosimilar share. The update matters for BD teams, investors, and analysts tracking EU regulatory catalysts and near-term competitive readouts.
EMA’s human-medicines readout for 2025 centres on 104 positive recommendations, including 38 new active substances. For BD teams and investors, the mix of biosimilars, orphan products, conditional approvals, and accelerated assessments matters more than the headline total alone.
Contents9 sections
Key Takeaways
- EMA recommended 104 human medicines for marketing authorisation in 2025; 38 contained a new active substance new to the EU.
- There were 41 biosimilar recommendations—called the highest annual total to date—with 23 containing denosumab.
- Sixteen medicines had orphan designation confirmed; three used accelerated assessment; eight received conditional marketing authorisation recommendations.
- These figures are CHMP/EMA recommendations sent to the European Commission, not automatic market launch dates.
What do the EMA approved drugs 2025 totals show?
On 15 January 2026, EMA published Human medicines in 2025, stating it recommended 104 medicines for marketing authorisation. Of these, 38 had a new active substance never authorised in the EU before.
Examples highlighted by EMA include the first medicine to treat non-cystic fibrosis bronchiectasis, a first-in-class treatment to delay onset of stage 3 type 1 diabetes in children and adults, and the first oral medicine to treat postpartum depression. Those examples illustrate therapeutic breadth; they are not a complete ranking of commercial value.
How large was the biosimilar and orphan share?
The companion PDF overview, Human medicines in 2025 (PDF), reports 41 biosimilar recommendations and notes that 23 of those biosimilars contain denosumab. EMA also states that since the biosimilar framework began in 2005, CHMP has assessed 181 biosimilar marketing-authorisation applications and approved 165 biosimilars.
- 16 medicines had orphan designation confirmed by 31 December 2025 (COMP review at approval).
- EMA’s news summary separately notes 16 medicines recommended for rare diseases, including a first medicine for Wiskott-Aldrich syndrome.
- Three positive opinions covered medicines for use in countries outside the EU under the EU-Medicines for all pathway, including a twice-yearly injectable HIV-1 PrEP option.
Which accelerated and conditional routes were used?
According to the same EMA PDF:
- Three medicines received a recommendation following accelerated assessment (maximum 150 days versus 210 days for standard assessment).
- Eight medicines received a recommendation for conditional marketing authorisation, with specific post-authorisation obligations to generate more complete data.
- Six PRIME-designated medicines were recommended for approval in 2025.
Conditional authorisation is early access with incomplete clinical data relative to standard requirements. For investors, the follow-up question is whether imposed obligations convert into full data packages on the agreed timetable.
What EMA’s 2025 annual report adds
EMA’s later release on its 2025 annual report repeats the 104 human-medicine and 38 new-active-substance figures and places them alongside veterinary recommendations. Use the annual report for agency-wide context; use the January human-medicines overview for the product-selection narrative and safety annex pointers.
What remains unproven from the annual tally
Recommendation counts do not equal reimbursement, launch sequencing, or U.S. FDA alignment. The overview also does not prove that every innovative example will become a commercial category leader. Negative opinions and withdrawn applications sit outside the 104 positive total and need separate tracking for competitive diligence.
Related NovaPharma coverage
- EMA board backs Ebola response, flags 2025 annual report
- EMA Post Authorisation Guidance Faces Evidence Gaps
- EMA Tightens Liver Safety Checks for Tavneos
Frequently Asked Questions
How many human medicines did EMA recommend in 2025?
EMA recommended 104 medicines for marketing authorisation in 2025. Of these, 38 had a new active substance never previously authorised in the EU.
How many biosimilars were recommended in 2025?
EMA reported 41 recommendations for new biosimilar products in 2025, described as the highest number ever approved in that framework’s history.
What special pathways featured in the 2025 totals?
Three medicines were recommended after accelerated assessment, eight received conditional marketing authorisation recommendations, and six PRIME-designated medicines were recommended for approval.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for denosumab.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
